MLchartDataset catalogue

anti-CTLA-4/OX40 bispecific antibody ATOR-1015

Term · Oncology and biomedicine · MLC-T-ONC-010561

A bispecific antibody consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitory protein fused to an OX40 agonistic human immunoglobulin G1 (IgG1) antibody, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CTLA-4/OX40 bispecific antibody ATOR-1015 simultaneously binds to CTLA-4 and OX40, which may inhibit CTLA-4-mediated downregulation of T-cell activation and induce proliferation of memory and effector T lymphocytes via OX40 activation. Both CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), and OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), are overexpressed by regulatory T cells (Tregs) in the tumor microenvironment. ATOR-1015 may reduce the number of Tregs and promote the activation of effector T cells, thereby enhancing the immune-mediated anti-tumor response.

Table 1. Record
IdentifierMLC-T-ONC-010561
FieldOncology and biomedicine
SynonymsCTLA-4 x OX40 bispecific antibody ATOR-1015
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010561",
  "term": "anti-CTLA-4/OX40 bispecific antibody ATOR-1015",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitory protein fused to an OX40 agonistic human immunoglobulin G1 (IgG1) antibody, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CTLA-4/OX40 bispecific antibody ATOR-1015 simultaneously binds to CTLA-4 and OX40, which may inhibit CTLA-4-mediated downregulation of T-cell activation and induce proliferation of memory and effector T lymphocytes via OX40 activation. Both CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), and OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), are overexpressed by regulatory T cells (Tregs) in the tumor microenvironment. ATOR-1015 may reduce the number of Tregs and promote the activation of effector T cells, thereby enhancing the immune-mediated anti-tumor response.",
  "synonyms": [
    "CTLA-4 x OX40 bispecific antibody ATOR-1015"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-ctla-4-ox40-bispecific-antibody-ator-1015/"
}

Record 1,654 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.